Business

Adicet Bio Stock jumps into the potential of investing.com to treat non-Hodgkin’s lymphoma

© Reuters.

By Sam Boughedda

Investing.com — Equity of Adicet Bio Inc (NASDAQ :) soared in trading Monday after reporting positive interim data from dose escalation in a phase I trial of a potential treatment for B-cell non-Hodgkin’s lymphoma. ..

Adicet shares were open and hit a high of $ 13.80 and are currently trading around $ 12.88, up 31%.

The company explained that as of November 22, at the time of the data cutoff, six patients were enrolled in a drug trial called ADI-001. The first two patients enrolled did not reach the rating, but three of the four evaluable patients achieved a response that included two complete responses and one partial response. ..

“The data so far suggest that ADI-001 is clinically very active. We will report additional data in the first half of 2022, revealing the potential of a gamma-delta CAR T cell platform for patients. We look forward to rapidly advancing the pipeline to maximize its potential, commented Chen Schor, President and CEO of Adicet Bio.

Disclaimer: Fusion media We inform you that the data contained on this website is not necessarily real-time or accurate. All CFDs (stocks, indices, futures) and forex prices are provided by the market maker, not the exchange, so prices may not be accurate and may differ from actual market prices. In other words, price is an indicator and is not suitable for trading purposes. Therefore, Fusion Media is not responsible for any transactional losses that may occur as a result of using this data.

Fusion media Alternatively, anyone involved with Fusion Media will not be liable for any loss or damage resulting from reliance on the data, quotes, charts, trading signals and other information contained on this website. Be fully informed about the risks and costs associated with financial market transactions. This is one of the most risky forms of investment possible.

Adicet Bio Stock jumps into the potential of investing.com to treat non-Hodgkin’s lymphoma

Source link Adicet Bio Stock jumps into the potential of investing.com to treat non-Hodgkin’s lymphoma

Related Articles

Back to top button